Ecallantide

Business Offer

United States

HAE is caused by a mutation of the C1-inhibitor gene. Defective or missing C1-inhibitor permits activation of kallikrein, a protease that is responsible for liberating bradykinin from its precursor kininogen. An excess of bradykinin leads to fluid leakage from blood vessels, causing swelling of tissues typical of HAE.Ecallantide suppresses this pathogenetic mechanism by selectively and reversibly inhibiting the activity of plasma kallikrein.https://www.creative-peptides.com/product/ecallantide-item-10-101-160-33646.html

[RequestAdvantages]

[RequestComments]

613

Cathy Miller